IMR Press / EJGO / Volume 41 / Issue 1 / DOI: 10.31083/j.ejgo.2020.01.4901
Open Access Case Report
HMGCR antibody-associated myopathy in patient with endometrial cancer: a rare case
Show Less
1 Department of Obstetrics and Gynecology, Osaka City University Graduate School of Medicine, Osaka, Japan
Eur. J. Gynaecol. Oncol. 2020 , 41(1), 148–150;
Published: 15 February 2020

Background: Anti-3-hydroxy-3-methylglutaryl coenzyme A reductase antibody (HMGCR antibody) antibody-associated myopathy is a rare disease. HMGCR antibody-associated myopathy in patient with endometrial cancer is extremely rare. Case Report: A 60-year-old woman without statin exposure presented with endometrial cancer Stage IIIC1 (T2N1M0) and HMGCR antibody-associated myopathy. After diagnosis, the patient received chemotherapy combining paclitaxel and carboplatin for endometrial cancer, and steroid and immunoglobulin for HMGCR antibody-associated myopathy. Two months after two cycles of chemotherapy, she died. Autopsy revealed that she died of HMGCR antibody-associated myopathy. Conclusion: In case of myopathy in patients with endometrial cancer, HMGCR antibody-associated myopathy should be considered.

Endometrial cancer
HMGCR antibody-associated myopathy
Figure 1.
Back to top